New drug trial aims to wipe out lingering leukemia cells after chemo
NCT ID NCT06570915
Summary
This study is testing an existing drug, daratumumab, for adults with a hard-to-treat type of leukemia called T-ALL. It's for patients who have responded to standard chemotherapy but still have tiny amounts of cancer cells left, which raises the risk of the disease coming back. The goal is to see if adding this drug can clear those remaining cells and help keep patients in remission longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.